Sugi Predict

Sugi Predict / Compounds / SCHEMBL202064

SCHEMBL202064

SCHEMBL202064

BrCc1nc(-c2cccs2)no1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.61
▸ NPC1 O15118 7/20 0.61
▸ SMN1; SMN2 Q16637 5/20 0.61
▸ MAPT P10636 4/20 0.61
▸ MCL1 Q07820 1/20 0.61
▸ TDP1 Q9NUW8 3/20 0.57
▸ L3MBTL1 Q9Y468 3/20 0.57
▸ PKM P14618 1/20 0.57
▸ TSHR P16473 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ GAA P10253 1/20 0.54
▸ LMNA P02545 4/20 0.53
▸ HDAC8 Q9BY41 3/20 0.52
▸ HDAC1 Q13547 2/20 0.52
▸ HDAC2 Q92769 2/20 0.52
▸ ATM Q13315 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ HPGD P15428 1/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ NFKB1 P19838 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1486703 0.83 RAB9A (0.61) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL12434381 0.83 RAB9A (0.61) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL4439807 0.83 RAB9A (0.61) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL8888284 0.83 MCL1 (0.65) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL4442344 0.81 MCL1 (0.66) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL4440742 0.78 MCL1 (0.63) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL4440934 0.77 HDAC1 (0.62) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL14946436 0.76 RAB9A (0.64) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL6325635 0.76 MCL1 (1.00) RAB9ANPC1SMN1; SMN2MAPTMCL1
SCHEMBL19287090 0.75 MCL1 (0.62) RAB9ANPC1SMN1; SMN2MAPTMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115093377-B Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2023-04-07 — — CN claimed
CN-115093377-A Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2022-09-23 — — CN claimed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 — — US disclosed
CN-115093377-B Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2023-04-07 — — CN disclosed
CN-115093377-A Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2022-09-23 — — CN disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 — — US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 — — US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 — — US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 — — US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 — — US disclosed
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 — — US disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 — — EP disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 — — WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 — — US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 — — US disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 — — EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 RAB9A 1340/4885NPC1 1786/4885SMN1; SMN2 2959/4885
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 RAB9A 1698/4885NPC1 418/4885SMN1; SMN2 1096/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 RAB9A 2799/4885NPC1 1400/4885SMN1; SMN2 1208/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 RAB9A 2799/4885NPC1 1400/4885SMN1; SMN2 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.